Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study ...

NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ...

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.4 which represents a decrease of $-0.10 or -4.00% from the prior close of $2.5. The stock opened at $2.44 and touched a low of $2.

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.04 or -1.67% from the prior close of $2.4. The stock opened at $2.36 and touched a low of $2 ...

Cassava Sciences has a 12-month low of $2.23 and a 12-month high of $42.20. The business’s fifty day simple moving average is $12.39 and its 200-day simple moving average is $19.58. Get Cassava ...

Notable profits for the buyer who lifted the $0.25 offer for 9,851 Cassava Sciences (SAVA) Feb-25 3 calls yesterday at 10:51ET when underlying shares were trading at $2.65. Shares closed at $2.75 ...

THE LAWSUIT: A class action securities lawsuit was filed against Cassava Sciences, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

Wellington Management Group LLP bought a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) during ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage ...